Matinas BioPharma Holdings Inc (NYSEAMERICAN:MTNB) was the recipient of a significant decline in short interest during the month of January. As of January 31st, there was short interest totalling 1,225,623 shares, a decline of 8.0% from the January 12th total of 1,331,591 shares. Based on an average daily volume of 142,829 shares, the days-to-cover ratio is presently 8.6 days. Currently, 1.7% of the company’s stock are short sold.

Shares of Matinas BioPharma (NYSEAMERICAN MTNB) opened at $0.91 on Wednesday. The firm has a market capitalization of $82.73, a P/E ratio of -2.46 and a beta of 0.38. Matinas BioPharma has a 52 week low of $0.83 and a 52 week high of $3.99.

Matinas BioPharma (NYSEAMERICAN:MTNB) last posted its earnings results on Wednesday, November 15th. The company reported ($0.04) earnings per share for the quarter, topping the consensus estimate of ($0.05) by $0.01. The firm had revenue of $0.05 million during the quarter, compared to analysts’ expectations of $0.05 million. Matinas BioPharma had a negative return on equity of 195.09% and a negative net margin of 7,558.92%.

A number of hedge funds have recently bought and sold shares of the stock. BlackRock Inc. lifted its stake in Matinas BioPharma by 3.4% during the fourth quarter. BlackRock Inc. now owns 2,530,508 shares of the company’s stock worth $2,935,000 after purchasing an additional 84,226 shares during the last quarter. Yellowstone Partners LLC purchased a new stake in Matinas BioPharma during the third quarter worth approximately $190,000. American Century Companies Inc. purchased a new stake in Matinas BioPharma during the fourth quarter worth approximately $155,000. Finally, Virtu Financial LLC lifted its stake in Matinas BioPharma by 126.0% during the fourth quarter. Virtu Financial LLC now owns 106,146 shares of the company’s stock worth $123,000 after purchasing an additional 59,188 shares during the last quarter.

COPYRIGHT VIOLATION NOTICE: This piece of content was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece of content on another website, it was copied illegally and reposted in violation of U.S. and international trademark & copyright law. The correct version of this piece of content can be accessed at

Matinas BioPharma Company Profile

Matinas BioPharma Holdings, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in identifying and developing therapeutics for the treatment of serious and life-threatening infections. It is engaged in developing a pipeline of product and development candidates, with an initial focus on serious fungal and bacterial infections.

Receive News & Ratings for Matinas BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Matinas BioPharma and related companies with's FREE daily email newsletter.